Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has received first Japanese patent for its small molecule anticancer drug LOR-253 that will provide Lorus with exclusive rights to LOR-253 in Japan until 2023.
Subscribe to our email newsletter
The patent will provide protection for LOR-253 composition of matter along with the coverage of Lorus lead antimicrobial small molecule LOR-220, which is used to treat drug resistant bacterial infections.
Lorus president and CEO Aiping Young said the Japanese patent is an addition to the Lorus global IP portfolio.
"Japan is a large and important market for drug therapies, and we believe this new patent should enhance partnering opportunities for both LOR-253 and LOR-220," Young added.
LOR-253 has been optimized to inhibit the cancer target Metal-Responsive Transcription Factor 1 (MTF-1) while LOR-220 targets a class of novel bacterial proteins called kinases.